G
George M. Rodgers
Researcher at University of Utah
Publications - 250
Citations - 10353
George M. Rodgers is an academic researcher from University of Utah. The author has contributed to research in topics: Endothelial stem cell & Tissue factor. The author has an hindex of 45, co-authored 244 publications receiving 9845 citations. Previous affiliations of George M. Rodgers include United States Department of Veterans Affairs & Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
Preeclampsia: an endothelial cell disorder.
James M. Roberts,Robert N. Taylor,Thomas J. Musci,George M. Rodgers,Carl A. Hubel,Margaret K. McLaughlin +5 more
TL;DR: It is proposed that poorly perfused placental tissue releases a factor(s) into the systemic circulation that injuries endothelial cells and set in motion a dysfunctional cascade of coagulation, vasoconstriction, and intravascular fluid redistribution that results in the clinical syndrome of preeclampsia.
Journal ArticleDOI
Evidence of increased angiogenesis in patients with acute myeloid leukemia
TL;DR: It is observed that the HL-60 and U937 human AML cell lines and 4 of 4 freshly isolated AML cells from untreated patients expressed mRNA for vascular endothelial growth factor (VEGF) and basic fibroblast growth factor was expressed only in HL- 60 cells and in only 3 of 4 fresh AML samples.
Journal ArticleDOI
Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells.
George M. Rodgers,Marion T. Conn +1 more
TL;DR: Investigation of the mechanism(s) by which homocysteine reduced protein C activation indicated that the metabolite did not induce an inhibitor to activated protein C, but in low concentrations acted as a competitive inhibitor to thrombin.
Journal ArticleDOI
Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator.
TL;DR: It is indicated that increased Factor V activity associated with homocysteine-treated vascular endothelium results primarily from induction of an activator of Factor V.
Journal ArticleDOI
Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.
Geno Merli,Theodore E. Spiro,Carl-Gustav Olsson,Ulrich Abildgaard,Bruce L. Davidson,Amiram Eldor,Darlene Elias,Andrew P. Grigg,Dominique Musset,George M. Rodgers,Arthur A. Trowbridge,Roger D. Yusen,Krystyna Zawilska +12 more
TL;DR: This parallel-group, randomized, partially blinded, international, multicenter clinical trial compared continuously infused unfractionated heparin with two weight-adjusted dosages of enoxaparin administered subcutaneously once or twice daily to determine whether deep venous thrombosis was present at baseline and whether objective evidence of recurrence existed.